Ardelyx

ARDX · Nasdaq · United States

Share price · ARDX

$3.12-0.80 (-20.41%) 3M

close as of 2026-11-18 · 24h delayed · vol 4.7M (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ARDX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 4 Nov 2026+8.6%
  2. 7 Aug 2026-17.9%
  3. 29 Jun 2026-5.8%

    Nothing announced by ARDX that day or the session before.

  4. 26 Jun 2026-8.4%

    Nothing announced by ARDX that day or the session before.

  5. 1 May 2026+8.7%
  6. 24 Feb 2026+14.1%

    Nothing announced by ARDX that day or the session before.

  7. 20 Feb 2026-15.0%
  8. 20 Jan 2026+15.0%

    Nothing announced by ARDX that day or the session before.

  9. 9 Jan 2026+10.6%
  10. 8 Jan 2026+20.1%

Share of unusual movement by asset

For each asset, the share of ARDX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Tenapanor (Ibsrela) (Ibsrela)
events and moves
2shown from 8 days
Tenapanor (Xphozah) (Xphozah)
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—47%
Sessions with no dated event—53%

Assets

(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
NHE3 (sodium/hydrogen exchanger isoform 3)Small molecule
Irritable Bowel Syndrome
Irritable Bowel Syndrome with Constipation
Approved
NHE3 (sodium/hydrogen exchanger isoform 3)Small molecule
Chronic Kidney DiseaseHyperphosphatemia

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
February 2027 (1)
Tenapanor (Ibsrela)Phase 3Chronic Idiopathic Constipation (CIC)
Est. primary completion 2027-02-26 · NCT07382167 · CT.gov ↗
What to watch
2031 (1)
July 2031 (1)
Tenapanor (Ibsrela)Phase 3Irritable Bowel Syndrome With Constipation (IBS-C)
Est. primary completion 2031-07 · NCT05905926 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$128M$25M$46M+ $239M short-term inv.$0.7M$2.2M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$121M$26M$97M+ $185M short-term inv.$17M-$6.4M operating cash flowreport ↗
2026-Q1$94M$20M$31M+ $207M short-term inv.$38M-$32M operating cash flowreport ↗
2025-Q3$110M$18M$43M+ $200M short-term inv.$1.0M$0.4M operating cash flowreport ↗
2025-Q2$98M$16M$90M+ $148M short-term inv.$19M-$25M operating cash flowreport ↗
2025-Q1$74M$15M$31M+ $183M short-term inv.$41M-$38M operating cash flowreport ↗
2024-Q3$98M$15M$47M+ $143M short-term inv.$0.8M$0.5M operating cash flowreport ↗
2024-Q2$73M$13M$42M+ $144M short-term inv.$16M-$19M operating cash flowreport ↗
2024-Q1$46M$11M$36M+ $166M short-term inv.$27M-$36M operating cash flowreport ↗
2023-Q3$56M$8.6M$34M+ $131M short-term inv.—-$21M operating cash flowreport ↗
2023-Q2$22M$8.3M$30M+ $98M short-term inv.$17M-$15M operating cash flowreport ↗
2023-Q1$11M$9.1M$92M+ $38M short-term inv.$27M-$45M operating cash flowreport ↗
2022-Q3$5.0M$7.5M$62M+ $29M short-term inv.$23M-$25M operating cash flowreport ↗
2022-Q2$2.5M$9.7M$53M+ $28M short-term inv.$27M-$31M operating cash flowreport ↗
2022-Q1$0.5M$8.8M$47M+ $43M short-term inv.$28M-$28M operating cash flowreport ↗
2021-Q3$1.2M$24M$75M+ $66M short-term inv.$44M-$35M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$407M$72M$68M+ $197M short-term inv.$15M-$42M operating cash flowreport ↗

Ardelyx reported fiscal 2025 revenue of $407.32M, up 22.1% YoY, with R&D spend of $71.53M, up 36.7% YoY. Cash and equivalents were $68M, and the company reported a net loss of $61.6M, with a quarterly net burn of $61.6M.

During the year, Ardelyx submitted an IND for tenapanor in chronic idiopathic constipation (CIC) and, in January 2026, initiated the Phase 3 ACCEL trial (ten-03-301), with topline data expected in the second half of 2027. The company also announced a development program for RDX10531, a next-generation NHE3 inhibitor, with an IND submission planned for the second half of 2026. In February 2025, Fosun Pharma received NMPA approval for tenapanor for hyperphosphatemia in hemodialysis patients in China. XPHOZAH’s inclusion in the ESRD PPS on January 1, 2025 negatively and materially impacted XPHOZAH revenue in 2025. Ardelyx drew an additional $50M under its term loan facility in Q2 2025, leaving $200M drawn and outstanding at year-end, and established a $100M at-the-market facility under which no shares had been sold as of December 31, 2025.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$334M$52M$65M+ $185M short-term inv.$9.8M-$45M operating cash flowreport ↗
2023-FY$124M$36M$21M+ $163M short-term inv.$17M-$90M operating cash flowreport ↗
2022-FY$52M$35M$96M+ $28M short-term inv.$17M-$70M operating cash flowreport ↗
2021-FY$10M$91M$72M+ $44M short-term inv.$40M-$153M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($1.9M), 78 sales ($4.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-21RAAB MICHAEL · director, President & CEOOpen-market sale15,009$3.86$58KForm 4
2026-08-21Williams Laura A · Chief Patient OfficerOpen-market sale3,486$3.86$13KForm 4
2026-08-21Kelliher Mike · Chief Business OfficerOpen-market sale3,104$3.86$12KForm 4
2026-08-21Foster Eric Duane · Chief Commercial OfficerOpen-market sale2,598$3.86$10KForm 4
2026-08-21Brady James Parker · Chief Human Resources OfficerOpen-market sale1,976$3.86$8KForm 4
2026-08-21Bishop John E · See RemarksOpen-market sale17,281$3.86$67KForm 4
2026-08-21Reilly Joseph James · See RemarksOpen-market sale2,872$3.86$11KForm 4
2026-08-21Hohenleitner Susan · Chief Financial OfficerOpen-market sale1,558$3.86$6KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 236 reporting institutions held 169.4M shares ($999.9M, 67.4% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.21,164,132$126.8M
2MILLENNIUM MANAGEMENT LLC17,842,370$106.9M
3STATE STREET CORP13,604,307$81.5M
4VANGUARD CAPITAL MANAGEMENT LLC10,365,512$62.1M
5JANUS HENDERSON GROUP PLC8,371,234$50.1M
6NOMURA ASSET MANAGEMENT INTERNATIONAL INC.8,169,369$48.9M
7VANGUARD PORTFOLIO MANAGEMENT LLC6,661,693$39.9M
8GEODE CAPITAL MANAGEMENT, LLC6,007,455$36.0M
9Nuveen, LLC5,234,683$31.4M
10TWO SIGMA INVESTMENTS, LP4,274,043$25.6M
11CITADEL ADVISORS LLC3,464,774$20.8M
12GOLDMAN SACHS GROUP INC3,216,210$19.3M
13J. Goldman & Co LP3,000,513$18.0M
14Point72 Asset Management, L.P.2,984,261$17.9M
15AQR CAPITAL MANAGEMENT LLC2,439,450$14.6M